Sign up to save your podcasts
Or
Share Duncan Emerton at Pharma Intelligence on the biosimilars opportunity propelling Biocon’s $3.3 bln Viatris deal
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Duncan Emerton at Pharma Intelligence on the biosimilars opportunity propelling Biocon’s $3.3 bln Viatris deal
Our guest today is Duncan Emerton, executive director, custom intelligence and analytics, at Informa Pharma Intelligence. Informa is a UK based business intelligence provider and consultancy. In this episode, Duncan explains some of the basics of why biosimilars are a huge opportunity and how Biocon’s deal to purchase the biosimilars unit of its long-term partner Viatris ticks several boxes for the Bangalore company.
(00:40) Introduction to The Daily Tech Conversation
(00:52) Our guest today — Duncan Emerton, executive director, custom intelligence and analytics, Informa Pharma Intelligence
(01:42) A snapshot of Duncan’s work and expertise
(03:01) A layman's definition of biosimilars, and how they are different from generics of chemical drugs
(04:42) A very brief history of biologics and biosimilars
(09:48) Reasons for the strong interest in biosimilars in the biopharma sector
(13:22) On the significance of Biocon’s $3.3 billion deal to buy the biosimilars unit of Viatris
(17:14) The tactical and longer-term strategic reasons for Biocon’s deal
(19:57) The timeframe over which Biocon could commercialise the parts of the Viatris biosimilars portfolio that it wasn’t already making under its existing partnership
(21:30) Thoughts on the potential risks involved in the deal
(23:44) The biggest trends in how drug companies are approaching R&D, after Covid
(26:27) Some of the biggest takeaways on using digital technologies that came out of Covid
(29:06) On how AI might help accelerate drug discovery and commercialisation
(30:57) Some final thoughts on the state of the biopharma industry
Biocon’s press release
https://www.biocon.com/docs/PR_BBL_Acquires-ViatrisBiosimilars-Business_Feb%2027.pdf
More about Duncan and Informa
https://pharmaintelligence.informa.com/about/meet-the-team/duncan-emerton
Theme music courtesy Free Music & Sounds:
https://soundcloud.com/freemusicandsounds
View all episodes
By Forbes India - Tech ConversationsOur guest today is Duncan Emerton, executive director, custom intelligence and analytics, at Informa Pharma Intelligence. Informa is a UK based business intelligence provider and consultancy. In this episode, Duncan explains some of the basics of why biosimilars are a huge opportunity and how Biocon’s deal to purchase the biosimilars unit of its long-term partner Viatris ticks several boxes for the Bangalore company.
(00:40) Introduction to The Daily Tech Conversation
(00:52) Our guest today — Duncan Emerton, executive director, custom intelligence and analytics, Informa Pharma Intelligence
(01:42) A snapshot of Duncan’s work and expertise
(03:01) A layman's definition of biosimilars, and how they are different from generics of chemical drugs
(04:42) A very brief history of biologics and biosimilars
(09:48) Reasons for the strong interest in biosimilars in the biopharma sector
(13:22) On the significance of Biocon’s $3.3 billion deal to buy the biosimilars unit of Viatris
(17:14) The tactical and longer-term strategic reasons for Biocon’s deal
(19:57) The timeframe over which Biocon could commercialise the parts of the Viatris biosimilars portfolio that it wasn’t already making under its existing partnership
(21:30) Thoughts on the potential risks involved in the deal
(23:44) The biggest trends in how drug companies are approaching R&D, after Covid
(26:27) Some of the biggest takeaways on using digital technologies that came out of Covid
(29:06) On how AI might help accelerate drug discovery and commercialisation
(30:57) Some final thoughts on the state of the biopharma industry
Biocon’s press release
https://www.biocon.com/docs/PR_BBL_Acquires-ViatrisBiosimilars-Business_Feb%2027.pdf
More about Duncan and Informa
https://pharmaintelligence.informa.com/about/meet-the-team/duncan-emerton
Theme music courtesy Free Music & Sounds:
https://soundcloud.com/freemusicandsounds